Literature DB >> 15316526

Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency.

Christopher A Bates1, Misoo C Ellison, David A Lynch, Carlyne D Cool, Kevin K Brown, John M Routes.   

Abstract

BACKGROUND: Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by low levels of serum immunoglobulins and an inability to make specific antibodies.
OBJECTIVE: We sought to determine the prevalence, clinical characteristics, and effect on survival of noninfectious pulmonary disease in patients with CVID.
METHODS: A retrospective analysis of 69 patients with CVID was performed. Patients were divided into 3 groups on the basis of the type of pulmonary disease present: group 1 (n=29), no pulmonary disease; group 2 (n=23), chronic respiratory symptoms without diffuse radiographic abnormalities; and group 3 (n=18), chronic respiratory symptoms and diffuse radiographic abnormalities. Group 3 patients were divided into 2 subgroups on the basis of the histopathologic pattern seen on biopsy. Group 3A (n=13) included patients with granulomatous lung disease, lymphocytic interstitial pneumonia, follicular bronchiolitis, and lymphoid hyperplasia, a group of syndromes referred to as granulomatous-lymphocytic interstitial lung disease (GLILD). Group 3B (n=5) consisted of patients with all other types of interstitial lung disease (ILD).
RESULTS: Fifty-eight percent of patients with CVID had noninfectious pulmonary complications. Group 3A (GLILD) patients had worse prognosis than the other groups, with a median survival of 13.7 versus 28.8 years (P<.001). Lymphoproliferative disease occurred in 31% of patients with GLILD. GLILD was associated with the presence of dyspnea (P<.05); splenomegaly (P<.05); restrictive pulmonary physiology; consolidation, ground-glass, and reticular radiographic abnormalities; and low CD3+ (P<.05) and CD8+ cell populations (P<.01).
CONCLUSION: ILD is common in patients with CVID. The presence of GLILD was associated with a worse prognosis and increased prevalence of lymphoproliferative disorders.

Entities:  

Mesh:

Year:  2004        PMID: 15316526     DOI: 10.1016/j.jaci.2004.05.057

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  88 in total

1.  Airway and interstitial lung disease are distinct entities in paediatric common variable immunodeficiency.

Authors:  A A J M van de Ven; P A de Jong; D P Hoytema van Konijnenburg; O A M Kessels; M Boes; E A M Sanders; S W J Terheggen-Lagro; J M van Montfrans
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

2.  Progression of Common Variable Immunodeficiency Interstitial Lung Disease Accompanies Distinct Pulmonary and Laboratory Findings.

Authors:  Paul J Maglione; Jessica R Overbey; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2015-09-12

3.  Granulomatous-lymphocytic interstitial lung disease and recurrent sinopulmonary infections in a patient with Good's syndrome.

Authors:  Mads Lynge Jensen; Elisabeth Bendstrup; Ole Hilberg
Journal:  BMJ Case Rep       Date:  2015-09-30

4.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

Review 5.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

Review 6.  Common variable immune deficiency: reviews, continued puzzles, and a new registry.

Authors:  Charlotte Cunningham-Rundles; Adina Kay Knight
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Granulomatous lymphocytic interstitial lung disease in infancy.

Authors:  Adetayo Adeleye; Magaret Kelly; Nicola Am Wright; Weiming Yu; Mark A Anselmo
Journal:  Can Respir J       Date:  2013-11-28       Impact factor: 2.409

8.  Granulomatous disease: distinguishing primary antibody disease from sarcoidosis.

Authors:  D F Arnold; J Wiggins; C Cunningham-Rundles; S A Misbah; H M Chapel
Journal:  Clin Immunol       Date:  2008-05-16       Impact factor: 3.969

9.  CT screening for pulmonary pathology in common variable immunodeficiency disorders and the correlation with clinical and immunological parameters.

Authors:  L J Maarschalk-Ellerbroek; P A de Jong; J M van Montfrans; J W J Lammers; A C Bloem; A I M Hoepelman; P M Ellerbroek
Journal:  J Clin Immunol       Date:  2014-06-21       Impact factor: 8.317

10.  30-Year Review of Pediatric- and Adult-Onset CVID: Clinical Correlates and Prognostic Indicators.

Authors:  Carolyn Baloh; Anupama Reddy; Michele Henson; Katherine Prince; Rebecca Buckley; Patricia Lugar
Journal:  J Clin Immunol       Date:  2019-08-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.